Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Voyager Therapeutics (VYGR) over the last 10 years, with Q3 2025 value amounting to $400000.0.

  • Voyager Therapeutics' Other Non Operating Income rose 10000.0% to $400000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 64863.64%. This contributed to the annual value of $622000.0 for FY2024, which is 2063333.33% up from last year.
  • Voyager Therapeutics' Other Non Operating Income amounted to $400000.0 in Q3 2025, which was up 10000.0% from $427000.0 recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' Other Non Operating Income registered a high of $3.9 million during Q1 2021, and its lowest value of -$1.6 million during Q2 2021.
  • Over the past 5 years, Voyager Therapeutics' median Other Non Operating Income value was $300000.0 (recorded in 2024), while the average stood at $530071.4.
  • Per our database at Business Quant, Voyager Therapeutics' Other Non Operating Income tumbled by 334130.43% in 2021 and then surged by 245446.43% in 2022.
  • Quarter analysis of 5 years shows Voyager Therapeutics' Other Non Operating Income stood at $650000.0 in 2021, then tumbled by 103.54% to -$23000.0 in 2022, then skyrocketed by 113.04% to $3000.0 in 2023, then soared by 13300.0% to $402000.0 in 2024, then fell by 0.5% to $400000.0 in 2025.
  • Its last three reported values are $400000.0 in Q3 2025, $427000.0 for Q2 2025, and $418000.0 during Q1 2025.